灵康药业(603669) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 reached ¥89,552,626.84, representing a year-on-year increase of 137.26%[2] - The net profit attributable to shareholders for Q3 2024 was -¥6,489,699.32, with a year-to-date net profit of -¥46,889,888.23[2] - The basic earnings per share for Q3 2024 was -¥0.01, and the diluted earnings per share was also -¥0.01[3] - The company achieved a year-to-date operating revenue increase of 53.34%, driven by enhanced product promotion and channel utilization[6] - Total operating revenue for the first three quarters of 2024 reached ¥231,030,545.43, a significant increase of 53.3% compared to ¥150,665,541.41 in the same period of 2023[19] - The company reported a net loss of ¥46,889,888.23 for the first three quarters of 2024, an improvement from a net loss of ¥96,582,500.85 in the same period of 2023[21] - Operating profit (loss) improved to -¥52,997,337.55 from -¥93,993,126.65 year-over-year[21] - Basic and diluted earnings per share improved to -¥0.07 from -¥0.13 year-over-year[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,205,651,919.73, a decrease of 25.79% compared to the end of the previous year[3] - The total assets decreased to ¥1,205,651,919.73 from ¥1,624,560,125.88, a decline of 25.7%[18] - The company’s equity attributable to shareholders decreased by 8.09% year-on-year, totaling ¥855,722,332.04[3] - The total liabilities decreased to ¥349,929,587.69 from ¥693,517,978.39, a reduction of 49.6%[18] - Current assets totaled RMB 495,170,740.50, down from RMB 881,533,254.03 in the previous period, indicating a significant reduction[16] - Non-current assets totaled RMB 710,481,179.23, down from RMB 743,026,871.85, indicating a decrease of about 4%[17] Cash Flow - The company reported a net cash flow from operating activities of -¥64,056,674.63 for the year-to-date period[3] - The net cash flow from operating activities for the first three quarters of 2024 was -64,056,674.63 RMB, compared to -21,150,724.69 RMB in the same period of 2023, indicating a decline in operational cash flow[25] - Total cash inflow from operating activities decreased to 211,980,745.20 RMB in 2024 from 260,896,973.39 RMB in 2023, reflecting a year-over-year decline of approximately 18.7%[25] - Cash outflow from operating activities was 276,037,419.83 RMB in 2024, slightly down from 282,047,698.08 RMB in 2023, showing a decrease of about 2.5%[25] - The company reported a significant reduction in cash flow from operations, impacting liquidity and operational flexibility[16] Investments and Financing - The company received government subsidies amounting to ¥14,483,829.44 year-to-date, which positively impacted its financial performance[4] - Cash inflow from investment activities was 196,544,899.48 RMB in 2024, significantly lower than 599,270,726.35 RMB in 2023, representing a decline of approximately 67.2%[25] - The net cash flow from investment activities improved to 185,104,669.99 RMB in 2024, compared to -89,657,920.92 RMB in 2023, indicating a positive turnaround[25] - Cash inflow from financing activities was 222,004,918.60 RMB in 2024, up from 118,646,944.44 RMB in 2023, marking an increase of approximately 87.2%[25] - The net cash flow from financing activities was -314,288,040.40 RMB in 2024, worsening from -4,127,640.96 RMB in 2023, indicating increased financial strain[25] Operational Changes - The company is actively seeking CMO orders to maximize production capacity and reduce costs[7] - There were no new product launches or major strategic initiatives mentioned during the earnings call, indicating a focus on financial restructuring and cost management[16] - Research and development expenses decreased to ¥14,987,666.90, down 29.5% from ¥21,226,696.58 in the previous year[19] - The company reported a significant increase in cash paid for purchasing goods and services, rising to 145,189,289.44 RMB in 2024 from 107,302,510.84 RMB in 2023, an increase of approximately 35.3%[25] - Cash paid for employee compensation decreased to 36,462,803.02 RMB in 2024 from 41,659,416.41 RMB in 2023, reflecting a decrease of about 12.0%[25]